figuring out the actual risk of COX-2 inhibitors

Experts are getting closer to figuring out the actual risk of COX-2 inhibitors...and how to use them appropriately.

The FDA will leave them on the market...with significant warnings.

Vioxx might even come back, now that we know cardiovascular problems aren't unique to Vioxx...and it's the ONLY one so far PROVEN to have GI benefits.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote